Wednesday, August 10, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

Profectus Biosciences Awarded Funding for Ebola Vaccine

by Global Biodefense Staff
October 15, 2014
Ebola Vaccine Research

The Department of Health and Human Services Office of the Assistant Secretary for Preparedness & Response (ASPR) this week awarded funding to Profectus BioSciences, Inc. to support advanced development of the company’s rVSV-vectored Ebola and Marburg virus vaccine.

The vaccine is based on the live attenuated rVSVINN4CT1 clinical vector, which has successfully completed phase 1 safety and immunogenicity testing as an HIV vaccine candidate (HVTN trial 090).

To provide protection against all filoviruses, the Profectus vaccine contains a blend of three rVSVN4CT1 vectors expressing the G proteins from S-EboV, Z-EboV, and MarV. In support of animal model development, Profectus provided the Z-EboV-rVSVN4CT1 and MarV-rVSVN4CT1 vaccines for two FANG-coordinated non-human primate challenge studies conducted under NIAID’s preclinical services program.

In an early study, a single IM dose of the Z-EboV-rVSVN4CT1 vaccine completely protected 3 cynomolgus macaques against challenge 28 days later with a lethal dose (1,000 pfu) of low passage Z-EboV, while 3 non-vaccinated macaques succumbed to lethal disease. Twenty eight days after the first challenge, the protected macaques were then challenged with a lethal dose (1,000 pfu) of low passage S-EboV. Two of three were protected, even though S-EboV is distantly related to Z-EboV.

In a second study, a single dose of the MarV-rVSVN4CT1 vaccine completely protected 2 cynomolgus macaques against lethal challenge 28 days later with low passage MarV, while 2 non-vaccinated macaques succumbed.

Additional biodefense programs at Profectus include vaccines against Lassa and Chikungunya viruses utilizing the vesiculovirus platform.

The contract is valued at $8,620,131 and was announced under Solicitation Number: CBRN-BAA-13-100-SOL-00013.

Tags: Animal ModelsASPREbolaHHSLassa FeverMarburgVaccines

Related Posts

Bacteria That Causes Melioidosis Confirmed in Environmental Samples in Mississippi Gulf Coast
Pathogens

Bacteria That Causes Melioidosis Confirmed in Environmental Samples in Mississippi Gulf Coast

July 27, 2022
Monkeypox Transmission: Virus Detected in Saliva, Bodily Fluids
Infectious Diseases

Monkeypox Transmission: Virus Detected in Saliva, Bodily Fluids

July 17, 2022
Influenza Transmission Spikes During Social Gatherings
Medical Countermeasures

New Universal Flu Vaccine Offers Broad Protection Against Influenza A Virus Infections

July 17, 2022
Pathogen Crescendo: Brass, Woodwinds Section Emit Respiratory Particles
Pathogens

Pathogen Crescendo: Brass, Woodwinds Section Emit Respiratory Particles

July 16, 2022
Load More

Latest News

Bacteria That Causes Melioidosis Confirmed in Environmental Samples in Mississippi Gulf Coast

Bacteria That Causes Melioidosis Confirmed in Environmental Samples in Mississippi Gulf Coast

July 27, 2022
Monkeypox Transmission: Virus Detected in Saliva, Bodily Fluids

Monkeypox Transmission: Virus Detected in Saliva, Bodily Fluids

July 17, 2022
Influenza Transmission Spikes During Social Gatherings

New Universal Flu Vaccine Offers Broad Protection Against Influenza A Virus Infections

July 17, 2022
Long COVID: National Academies’ Panel Examines Long-Term Health Effects of COVID-19

Long COVID: National Academies’ Panel Examines Long-Term Health Effects of COVID-19

July 17, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC